Clinical trial · Observational
Detection of Plasma Circulating Tumor DNA in Gastric Cancer
NCT05027347CI-TRIAL-00058102unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to develop a protocol for detection of circulating tumor DNA (ctDNA) in plasma of patients with early stages of gastric cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Circulating Tumor DNA (ctDNA) | Gastric Neoplasm | PROBABILISTIC | 0.70 |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| plasma circulating tumor DNA | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- 100 healthy people
- description
- 10 ml blood and tissue biopsy were collected from each patient
- interventionNames
- Diagnostic Test: plasma circulating tumor DNA
- label
- 100 gastric cancer patients
- description
- 10 ml blood and tissue biopsy were collected from each patient
- interventionNames
- Diagnostic Test: plasma circulating tumor DNA
Primary outcomes (1)
- measure
- The sensitivity and and specificity of our mutation-based assay for detecting early-stage gastric cancer patients
- timeFrame
- 1 months after collecting blood and specimen
- description
- sensitivity and and specificity of our mutation-based assay for detecting early-stage gastric cancer patients
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male or Female patients aged 18 years and older 2. Histologically proven stage (I, II and IIIA) gastric adenocarcinoma 3. Naivety to treatment. 4. No known other concomitant cancer diagnosis 5. Signed informed consent Exclusion Criteria: 1. Pathologically late stage (stage IIIB and IV) or metastatic gastric adenocarcinoma 2. Underwent any type of treatment 3. Unable to undergo biopsy
References
Publications (0)
Data not yet available
No reference posted for this study.